搜索结果

   UGT2B15

靶点ID:TCMBANKGE004778

靶点别名:HLUG4; UDPGT 2B8; UDPGT2B15; UDPGTH3; UGT2B8

靶点描述:UDP glucuronosyltransferase family 2 member B15

染色体:4

染色体位置:4q13.2

靶点类型:protein-coding

HERB_ID:-

HGNC_Link:12546

OMIM_Link:600069

Ensembl_Link:ENSG00000196620

   靶点对应的植物
ID 拉丁名 药名 药用植物名 功能与主治 来源 药用部位 使用民族
   靶点对应的化合物
化合物ID 化合物名 别名 分子式 分子质量 Smiles
TCMBANKIN011449 baohuoside C27H30O10 CC1C(C(C(C(O1)OC2=C(OC3=C(C2=O)C(=CC(=C3CC=C(C)C)O)O)C4=CC=C(C=C4)OC)O)O)O
TCMBANKIN058196 4-hydroxy cinnamic acid;trans- p- hydroxy cinnamic acid;trans-p-coumaric acid;p-cumaric acid;4-coumaric acid;P-hydroxy- cinnamic acid;Hydroxycinnamic acid 4-hydroxycinnamic acid;trans-p-Hydroxycinnamic acid; Trans-p-hydroxy cinnamic acid;AS03322; I01-9546; I01-9648; Para-Coumaric acid; trans-p-Hydroxycinnamate; UNII-IBS9D1EU3J; 4-Hydroxycinamic acid; AK134594; AM20050138; trans-4-Hydroxycinnamic acid; Hydroxycinnamic acid; p-Coumaric acid, primary pharmaceutical reference standard; (E)-3-(4-Hydroxyphenyl)-2-propenoic acid; beta-[4-Hydroxyphenyl]acrylic acid; MP-2217; BP-13278; F2191-0188; IBS9D1EU3J; p-coumaric-acid; STL163567; BG00601173; 2-propenoic acid, 3-(4-hydroxyphenyl)-, (2E)-; 50940-26-6; TR-023948; p-Cumarate; Naringeninic acid; p-Cumaric acid; NCGC00246974-01; (E)-3-(4-Hydroxyphenyl)acrylic acid; CHEBI:36090; AS-12000; N1817; p-Coumaric acid,trans; TL8005115; 501-98-4; bmse010208; bmse000150; TIMTEC-BB SBB007613; DTXSID6064660; p-coumaric acid; NSC-674321; SCHEMBL39106; AKOS 221-47; AC1Q71H0; bmse000591; p-Coumaric acid, trans; MolPort-000-860-894; AE-562/40414679; COUMARIC ACID, TRANS-P-; 4-coumaric acid, (E)-isomer; trans-4-hydroxycinnamate; trans-p-Coumarinic acid; 3-(4-Hydroxyphenyl)-2-propenoate; (E)-3-(4-HYDROXY-PHENYL)-ACRYLIC ACID; LS30305; 3-(4-hydroxyphenyl)acrylic acid; (2E)-3-(4-hydroxyphenyl)prop-2-enoic acid; hydroxycinnamate; 4'-Hydroxycinnamate; SC-25929; trans-p-Hydroxycinnamic acid; (E)-p-Hydroxycinnamic acid; 3-(4-hydroxyphenyl)acrylate; PubChem24323; LS-54111; NGSWKAQJJWESNS-ZZXKWVIFSA-N; trans-4-coumaric acid; trans-p-Cumaric Acid; trans-p-Coumaric acid; AKOS BAR-2479; RTR-023948; RP09062; ZINC39811; 4-10-00-01005 (Beilstein Handbook Reference); 0C1BFF2D-2CF7-4FC1-9F76-3268C2C7F783; LS-54112; C00811; (2E)-3-(4-hydroxyphenyl)acrylic acid; ST2402517; Cinnamic acid, 4-hydroxy-, trans-; BG01501541; 4qem; BDBM4374; HMS1409E10; BRN 2207383; SC-65982; I04-0102; C9H8O3; (E)-3-[4-hydroxyphenyl]-2-propenoic acid; ATTERCOP-CHM AT113965; beta-(4-Hydroxyphenyl)acrylic acid; Para coumaric acid; BCP9001042; MLS001066419; p-Hydroxyphenylacrylic acid; Cinnamic acid, p-hydroxy-; RARECHEM BK HW 0163; 4-Coumaric acid; CS-W020394; TR-017943; p-Coumaric acid, >=98.0% (HPLC); (2E)-3-(4-Hydroxyphenyl)-2-propenoic acid; b-[4-Hydroxyphenyl]acrylate; Q-100560; 7400-08-0; BB_NC-2249; RP17402; BBL012226; AK-26304; W-104438; D0AU0M; p-hydroxycinnamic acid (M4); 2-Propenoic acid, 3-(4-hydroxyphenyl)-, homopolymer; SBB007613; 4-Hydroxycinnamate; ZX-AT011614; Cinnamic acid, p-hydroxy-, (E)-; p-Caumaric acid dehydrogenation homopolymer; SMR000112201; 4f8j; 0-10-00-00297 (Beilstein Handbook Reference); (E)-p-Coumaric acid; 4CN-0926; p-Hydroxycinnamate; (E)-4-hydroxycinnamic acid; 2-Propenoic acid, 3-(4-hydroxyphenyl)-; DB04066; trans-p-Coumaric acid, analytical standard; 2-Propenoic acid, 3-(4-hydroxyphenyl)-, (Z)-; .beta.-[4-Hydroxyphenyl]acrylic acid; p-Coumaricacid; AJ-08911; p-Hydroxy-cinnamic acid; 4-Hydroxy cinnamate; AC1LCUFZ; AKOS000120685; BR-26304; InChI=1/C9H8O3/c10-8-4-1-7(2-5-8)3-6-9(11)12/h1-6,10H,(H,11,12)/b6-3; Para coumarate; trans-p-coumarate; 4-Hydroxyphenylpropenoate; P-HYDROXYL CINNAMIC ACID; OTAVA-BB 7020400347; AC-10318; (E)-3-(4-hydroxyphenyl)prop-2-enoic acid; AN-287; LABOTEST-BB LT03329617; p-Hydroxycinnamic acid; MolPort-004-288-351; EINECS 231-000-0; p-Hydroxycinnamic acid, trans; KB-72564; TC-164240; BRN 2207381; 2-Propenoic acid, 3-(4-hydroxyphenyl)-, (E)-; ST24022578; 4-hydroxy cinnamic acid; NSC 674321; LABOTEST-BB LT00452637; Para-Coumarate; (2E)-3-(4-Hydroxyphenyl)-2-propenoic acid #; b-[4-Hydroxyphenyl]acrylic acid; 4'-hydroxycinnamic acid; beta-[4-Hydroxyphenyl]acrylate; NSC-59260; PubChem8247; 4-Hydroxycinnamic acid; CHEMBL66879; CHEBI:32374; BG01501540; NSC674321; RTR-017943; 2-Propenoic acid, 3-(4-hydroxyphenyl)-, (E)- (9CI); NSC59260; 400H080; AX8022446; 3-(4-Hydroxyphenyl)-2-propenoic acid; AC1Q5T95; 3-(4-hydroxyphenyl)prop-2-enoic acid; ST093691; GTPL5787; 4-coumarate; MFCD00004399; NSC 59260;p-hydroxy-cinnamic acid;p- hydroxycinnam icacid; p-hydroxycinnami cacid; p-hydroxy cinnamic acid; p-hydroxycinnamic acid C9H8O3 164.16 g/mol C1=CC(=CC=C1C=CC(=O)O)O
TCMBANKIN058213 kaemferol;kampferol;kaempferol;campherol TNP00039; nchembio.2007.28-comp30; Kaempherol; 5-18-05-00251 (Beilstein Handbook Reference); Prestwick2_001098; CHEBI:28499; Prestwick1_001098; CAS-520-18-3; BRN 0304401; Flavone, 3,4',5,7-tetrahydroxy-; ST030560; MEGxp0_001283; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-5,7,4'-Trihydroxyflavonol; C.I. 75640; Swartziol; K0133_SIGMA; kaempferol oxoanion; NCGC00016480-01; 60010_FLUKA; EINECS 208-287-6; Pelargidenon; Nimbecetin; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4-chromenone; NSC 407289; 3,4',5,7-Tetrahydroxyflavone; HSCI1_000027; Pelargidenolon 1497; NSC407289; Robigenin; C05903; CPD1F-90; Kampferol; NSC 656277; Prestwick0_001098; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; Populnetin; Kampcetin; Prestwick3_001098; AIDS-001404; ZINC00137345; kaempferol ; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-olate; 3,4′,5,7-Tetrahydroxyflavone; Rhamnolutein; NCGC00016480-02; ACon1_001867; NSC656277; 3,4′,5,7-Tetrahydroxyflavone; BSPBio_001176; SPBio_003058; Oprea1_650954; 5,7,4'-Trihydroxyflavonol; 4H-1-Benzopyran-4-one,3,5,7-trihydroxy-2-(4-hydroxyphenyl)-5,7,4'-Trihydroxyflavonol; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)- (9CI); Campherol; 520-18-3; 3,5,7-TRIHYDROXY-2-(4-HYDROXYPHENYL)-4H-CHROMEN-4-ONE; S00111; Trifolitin; Kampherol; AI3-36096; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromone; Indigo yellow; Pelargidenolon; AIDS001404; nchembio718-comp14; NCGC00091036-01; Flavone, 3,4',5,7-tetrahydroxy- (7CI,8CI); CHEBI:58573; Kaemferol; Kempferol; BPBio1_001294; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; Rhamnolutin; 3,5,7-triOH-Flavone; KMP; CCRIS 41; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)- C15H10O6 286.24 g/mol C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O
TCMBANKIN060110 oestrone C18H22O2 270.4 g/mol CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)O
TCMBANKIN060154 3,5,7-Trihydroxy-4'-methoxyl-8-prenylflavone-3-O-rhamnopyranoside C27H30O10 514.52 CC1C(C(C(C(O1)OC2=C(OC3=C(C(=CC(=C3C2=O)O)O)CC=C(C)C)C4=CC=C(C=C4)OC)O)O)O
   靶点对应的疾病
疾病ID 疾病名 MeSH名 HPO名 UMLS名 疾病类型
TCMBANKDI000166 - - Neoplastic Process disease
TCMBANKDI003248 Nutritional and Metabolic Diseases; Endocrine System Diseases Abnormality of metabolism/homeostasis; Abnormality of the endocrine system Disease or Syndrome disease
TCMBANKDI011743 Neoplasms; Skin and Connective Tissue Diseases Neoplasm; Abnormality of the breast Neoplastic Process group
TCMBANKDI020602 Male Urogenital Diseases Abnormality of the genitourinary system Disease or Syndrome disease
TCMBANKDI023464 Nervous System Diseases Abnormality of the nervous system Disease or Syndrome disease
TCMBANKDI025420 Digestive System Diseases; Neoplasms Abnormality of the digestive system; Neoplasm Neoplastic Process disease
TCMBANKDI031192 Neoplasms; Male Urogenital Diseases - Neoplastic Process disease
TCMBANKDI031879 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Endocrine System Diseases - Disease or Syndrome disease

Home | Browse | Search | Predict | Data | Contact | Help

Copyright © KUST | 滇IICP备16009434号-1 | Dai SX Lab